Source: https://www.wipo.int/amc/en/domains/decisions/html/2003/d2003-0733.html
Timestamp: 2019-04-20 16:51:25+00:00

Document:
The Complainants are A. Nattermann & Cie Gmbh, Köln, Germany and Aventis Pharma SA, Antony, France, represented by Selarl Marchais De Candé, France.
The Respondent is Bob Smith, Midland, Texas, United States of America.
The disputed domain name <lipostabilusa.com> is registered with eNom.
The Complaint was filed with the WIPO Arbitration and Mediation Center (the "Center") on September 16, 2003. On September 17, 2003, the Center transmitted by email to eNom a request for registrar verification in connection with the domain name at issue. Copy of the printout of WHOIS information, printed before the Notification of Complaint, confirms that the Respondent is listed as the registrant and provides the contact details for the administrative, billing, and technical contact. In response to a notification by the Center on September 23, 2003, that the Complaint was administratively deficient, the Complainants filed an amendment to the Complaint on September 26, 2003, by email, hardcopy of which was received on September 29, 2003. The Center verified that the Complaint together with the amendment to the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the "Policy"), the Rules for Uniform Domain Name Dispute Resolution Policy (the "Rules"), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the "Supplemental Rules").
In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on September 30, 2003. In accordance with the Rules, paragraph 5(a), the due date for the Response was October 20, 2003. The Notification of Complaint and Commencement of Administrative Proceeding and a copy of the Amended Complaint (with attachments) were dispatched by FEDEX courier and email to the Respondent. The tracking record of FEDEX shows that delivery of these documents was unsuccessful like, apparently, notification via email. On the other side, the Complainants stated in their amended Complaint that a copy thereof had been sent by registered letter to the Respondent on September 26, 2003 (Complaint, para. 17 p. 19).
The Panel is satisfied that the Center has complied with its obligations under paragraph 2(a) of the Rules "to employ reasonably available means calculated to achieve actual notice to Respondent" (see e.g. Charles Schwab & Co, Inc. v Polanski, WIPO Case No. D2001-0959).
The Respondent did not submit any response. Accordingly, the Center notified the Respondent�s default on October 21, 2003.
The Center appointed Christophe Imhoos as the sole panelist in this matter on October 30, 2003. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7, and rendered his decision within the time-limit granted.
AVENTIS Holding and its affiliate companies A.NATTERMANN & Cie Gmbh and AVENTIS PHARMA SA, the Complainants in this administrative proceeding, are leaders among the pharmaceutical companies in the world.
AVENTIS offers a wide range of patented prescription drug to treat patients whilst, in the field of dermatology, A.NATTERMANN, wholly owned by the AVENTIS Group, has notably developed and sells throughout the world drugs under the trademark "LIPOSTABIL" which is an intravenous drug product containing phosphatidylcholine (commonly called lecithin) which is a lipid lowering agent which has been approved in a number of countries for the prophylaxis and therapy of fat embolisms (Annex 5 to the Complaint) and has been sold in many countries around the world such as, for example, the European Countries, South Africa and South America.
The Complainant submits that AVENTIS PHARMA S.A. has been designated by AVENTIS SA to manage all the domain names belonging to the AVENTIS Group.
All of these trademarks are registered and are being used by their owner in connection with classes 1 and 5 of the international classification, i.e. pharmaceutical products.
(i) The domain name <lipostabilusa.com> is quite identical to the trademark "LIPOSTABIL" registered by the Complainants; the only difference is the suffix "usa" which is not such as significantly influencing the overall impression produced by the domain name dominated by the term "LIPOSTABIL".
The domain name <lipostabilusa.com> entirely reproduces the term "LIPOSTABIL" which is a neologism invented by A.NATTERMANN & Cie Gmbh and is therefore highly distinctive.
The word LIPOSTABIL is a contraction of the words "LIPOSUCTION" and "STABILISATION"; the mere addition of "usa" which is added in second position in front of the dot com is a term of secondary importance and is not sufficient to suppress the likelihood of confusion which stems from the use of the word LIPOSTABIL which is the main and attractive word.
Moreover, the term "usa" does not prevent the public from thinking that this domain name is somehow connected to the LIPOSTABIL trademark as it is well known that "usa" is the obvious acronym for United States of America. This confusion is emphasized by the fact that, in the pages of the website, the term "usa" appears in small characters, just under the word LIPOSTABIL. The word "usa" generates a likelihood of confusion for the consumers by letting them think that AVENTIS and A.NATTERMANN Gmbh agreed to the sale of LIPOSTABIL by the Respondent in the USA.
(ii) The Respondent should be considered as having no rights or legitimate interests in respect of the domain name that is the subject of the Complaint.
The Respondent, Bob SMITH, does not have any legitimate interest to use the domain name <lipostabilusa.com> since neither the term "Bob" nor the term "SMITH" has any resemblance with the word "LIPOSTABIL".
The domain name <lipostabilusa.com> leads to a home page describing the specifications of the drug created and sold by the Complainants (Annex 6 to the Complaint); moreover, a domain name <lipostabil2U.com>, registered by Rich SITES on June 24, 2003, leads to a very similar home page also describing the specifications of the drug created and sold by the Complainants (Annex 7.1 to the Complaint).
Moreover, Bob SMITH has never been authorized to present or sell LIPOSTABIL products or to use this trademark or to register any domain names incorporating the above-mentioned trademark.
As a result, the circumstances described under Paragraph 4(b)(iv) of the Policy are met.
In addition, LIPOSTABIL is mentioned as an AVENTIS� product on the Respondent�s websites (Annex 6.1. and Annex 7.1 to the Complaint).
The Respondent has clearly adopted the A.NATTERMANN & Cie Gmbh�s trademarks and AVENTIS� trade name for his own use, and incorporated them into his domain names without the authorization of the Complainants.
This use is strictly made in reference to the LIPOSTABIL trademarks. The absence of rights or legitimate interests of the Respondent in respect of the domain name is therefore demonstrated.
(iii) The domain name should be considered as having been registered and used in bad faith.
The Respondent was aware at the time of the registration of the litigious domain name of the existence of the drug named "LIPOSTABIL" developed and sold by A.NATTERMANN & Cie Gmbh and AVENTIS, and the trademark "LIPOSTABIL" owned by A.NATTERMANN & Cie Gmbh and AVENTIS.
The Respondent registered its domain name in order to abusively take benefit from the Complainants� notoriety. The LIPOSTABIL trademark has been created in the 50�s and since then, has become a world-famous trademark.
Moreover, by registering this name, the Respondent seeks to attract Internet users who mis-enter or misspell Complainants' name when seeking to find information about the LIPOSTABIL product.
The use made by the Respondent of the litigious domain name leads to a risk of confusion within the meaning of Paragraph 4(b)(iv) of the Policy.
The website contains a description of the LIPOSTABIL drug known for its use against fat and give the possibility to order it; the original packaging of the drugs sold by the AVENTIS Group is presented on the home page of the website (Annex 6.1 the Complaint); moreover, the Respondent�s website is used in reference to the trademark and trade name of the Complainants as on its website the Respondent keeps referring to AVENTIS (Annex 6 to the Complaint).
Consequently, the reproduction of the trademark, the trade name and the products of the Complainants, without having been authorized, creates a confusion for consumers who want information about the drug sold by AVENTIS and A.NATTERMANN & Cie Gmbh. The consumer may therefore believe that there is an official affiliation between the website "www.lipostabilusa.com" and the Complainants, especially since the Registrant has used the term "usa" which is the obvious acronym for United States of America, as if the Complainants agreed to the sell of LIPOSTABIL in the USA by the Respondent.
This confusion is emphasized by the fact that within the website the letter "U" is written in red, the letter "S" in write, and the letter "A" in blue, like the colour of the American flag, and that the term "usa" appears in small characters, just under the word "LIPOSTABIL".
Therefore, having undoubtedly the knowledge of the Complainants� trademark LIPOSTABIL, the Respondent can be assumed to have been aware of the risk of deception and confusion that would inevitably follow when using the domain name, since this could give the impression that the website, and thus the Respondent, was somehow endorsed by the Complainants.
Moreover, this domain name was registered and is being used for a commercial purpose as the domain name <lipostabilusa.com> is not only a website giving information to patients and consumers, but also selling LIPOSTABIL.
The Respondent creates a confusion for consumers who may believe that there is an official affiliation between the owners of the trademark, i.e. the Complainants, and the website "lipostabilusa.com". By using on this website the trademark of the drug sold by the Complainants, its original packaging and the trademark AVENTIS itself, the Respondent intentionally benefits of the fame of the trademark of the Complainants for financial gain.
The Administrative Panel has to decide the Complaint on the basis of the statements and documents submitted and in accordance with the Policy, the Rules and any rules and principles of law that it deems applicable, pursuant to Paragraph 15(a) of said Rules.
The Complainants have established their rights in the trademark "LIPOSTABIL" with various registrations for such a name (see Annex 4 to the Complaint), especially in the country where the Respondent is registered, i.e. in the USA.
The Complainants have submitted conclusive evidence that their trademark "LIPOSTABIL" is confusingly similar to the domain name <lipostabilusa.com>.
The main difference between the disputed domain name and the Complainants' mark is the addition of "usa" before the Complainants' mark which does not render the disputed domain name totally distinctive from the Complainants' trademark.
Administrative Panels have found domain names to be identical or at least confusingly similar when based on "close variant" or "close misspelling" of the mark in question (e.g. AltaVista Company v. Grandtotal Finances Limited et al., WIPO Case No. D2000-0848; Yahoo! Inc. v. Eitan Zviely et al., WIPO Case No. D2000-0273).
It can also be considered that the domain name in dispute reproduces the Complainants' trademark with the addition of a geographic term.
Various Administrative Panels also found that the addition of a geographic descriptor does not change the confusing nature of the similarity (e.g. Telstra Corporation Limited v. Ozurls WIPO Case No. D2001-0046; Wal-Mart Stores, Inc. v. Lars Stork, WIPO Case No. D2000-0628; America Online, Inc. v. Dolphin@Heart, WIPO Case No. D2000-0713; Wal-mart Stores, Inc. v. Yongsoo Hwang, NO-WALMART and NO-WALMART.COM, WIPO Case No. D2000-0838; AltaVista Company v. S.M.A., Inc., WIPO Case No. D2000-0927; Yahoo! Inc. v. Microbiz, Inc., WIPO Case No. D2000-1050; Viacom International Inc. v Sung Wook Choi and M Production, WIPO Case No. D2000-1114; Amway Corporation, Inc. v. Business Internet Connection and Rex Mehta, WIPO Case No. D2000-1118; Jefferson Smurfit Group plc v. Stephen Davidson Inc., WIPO Case No. D2000-1117; see also Yahoo! Inc v. Eitan Zviely et al., WIPO Case No. D2000-0273).
There is no reason in the instant matter to depart from these decisions under the circumstances described above and not rebutted by the Respondent.
For the above reasons, the Panel finds that the disputed domain is confusingly similar to Complainants' trademark "LIPOSTABIL".
The Respondent, in not responding to the Complaint, has failed to invoke any of the circumstances, which could demonstrate, pursuant to Paragraph 4(c) of the Policy, any rights to and/or legitimate interests in the domain name in dispute. This entitles the Administrative Panel to draw any such inferences from such default as it considers appropriate pursuant to Paragraph 14(b) of the Rules already cited above.
Absent evidence to the contrary, the Complainants, as underlined in their Complaint, have not granted any license or otherwise permitted the Respondent to use the trademark in question or to apply for any domain name incorporating the said trademark. In addition, the Respondent is not commonly known by the domain name in question as rightly submitted by the Complainants.
Furthermore, it is worth mentioning that the Respondent is doing nothing but using the domain name <lipostabilusa.com> for commercial purpose.
Under these particular circumstances, the Panel is unable to find any evidence that would tend to establish that the Respondent has rights or legitimate interests in respect of the domain name at stake.
As already mentioned, the Respondent did not file any response to the Complaint, failing thereby to invoke any circumstance, which could demonstrate his good faith in the registration or use of the domain name in issue.
Much to the contrary based on the contentions restated above, it is the Panel's finding that the Complainant has established, with conclusive evidence, (see Annex 6 to the Complaint) a prima facie case that the Respondent, clearly, behaved according to the circumstances described under Paragraph 4(b)(iv) of the Policy.
As regards bad faith registration, the Administrative Panel follows the Complainants' contentions that the Respondent was undoubtedly aware, at the time of the registration of the domain name in question, of the existence of the "LIPOSTABIL" product developed and sold by the Complainants.
Therefore, the Administrative panel finds that the domain name <lipostabilusa.com> should be considered as having been registered and used in bad faith.
For all the foregoing reasons, in accordance with Paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the domain name <lipostabilusa.com> be transferred to Aventis Pharma SA.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.